Mazda’s treatment of customers with defective vehicles was “appalling” and its statements about their entitlement to a refund were false or misleading, a judge has found in a partial win for the ACCC.
Victoria’s Alfred and St Vincent’s hospitals are the targets of a new class action filed on behalf of junior doctors alleging they were not paid for unrostered work that included admitting patients and attending to medical emergencies.
Banking giant Westpac has admitted to allegations in six new cases by the Australian Securities and Investments Commission alleging widespread compliance failures across multiple businesses, and will agree to pay a combined $100 million penalty.
Beach Energy has been hit with a second shareholder class action in as many days over allegedly misleading earnings projections for its Western Flank oil and gas reserves in the Cooper Basin.
A bid by Google for a confidentiality undertaking by former NSW Deputy Premier John Barilaro over evidence produced in the politician’s defamation case has earned a sharp rebuke by a judge.
The judge who made findings against the son of the mastermind behind the Banksia class action scam may have formed strong views about the 27-year-old’s role before he testified and used the flawed suggestion that he was his father’s right-hand man as an “evidential gap filler”, an appeals court has been told.
The Australian Securities and Investments Commission has launched court proceedings against ANZ alleging the banking giant’s home loan ‘introducer’ referral program breached credit laws.
The federal government’s latest class action reform bill that would effectively cap legal fees and funding commissions has narrowly passed the House of Representatives.
The insolvency administrator of Germany-based Greensill Bank AG has launched court proceedings against Insurance Australia Limited seeking US$35 million allegedly owed under a policy indemnifying the collapsed financial services firm for unrecovered debts.
Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.